Presentation is loading. Please wait.

Presentation is loading. Please wait.

SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.

Published byTobias Evans Modified over 9 years ago

Similar presentations

Presentation on theme: "SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir."— Presentation transcript:

1 SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir F4 or Ishak 5-6 or Fibroscan > 12.5 kPa or Fibrotest > 0.75 and APRI > 2 ASTRAL-3 Foster GR. N Engl J Med 2015; 373: 2608-17  Design  Objective –SVR 12 (HCV RNA < 15 UI/ml), by ITT : non-inferiority of SOF/VEL with a lower bound of 95% CI for difference of - 10%, 94% power ; if non-inferiority, test for superiority with significance level of 0.05 RBV (in 2 divided doses): 1000 mg if < 75 kg or 1200 mg/day if ≥ 75 kg > 18 years Chronic HCV infection Genotype 3 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis allowed** No HBV or HIV co-infection SVR 12 Randomisation* 1 : 1 Open-label ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3

2 SOF/VEL 12 weeks N = 277 SOF + RBV 24 weeks N = 275 Age, years, mean4950 Female39%37% White 90%87% HCV RNA, log 10 IU/ml, mean6.2 ± 0.726.3 ± 0.71 IL28B CC38%40% Cirrhosis29%30% Treatment experienced26% Response to previous HCV treatment No response Relapse 28% 72% 34% 66% Discontinuation, N Lack of efficacy Adverse event Lost to follow-up Non adherence Withdrew consent Death 21001002100100 21 1 9 4 2 3 2 Baseline characteristics and patient disposition ASTRAL-3 ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3 Foster GR. N Engl J Med 2015; 373: 2608-17

3 ASTRAL-3 *adjusted absolute difference : 14.8 (95% CI : 9.6 to 20.0) ; p < 0.001 = superiority  SVR 12 according to baseline NS5A RAVs in SOF/VEL group –Absent, N = 231 : SVR 12 = 97.4% –Present, N = 43, SVR 12 = 88.4% (84% if Y93H) ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3 SVR 12, % (95% CI) 0 20 40 60 80 100 95.3 (92.1-97.5) 277 SOF/VEL 12 weeks 275 SOF + RBV 24 weeks 80.4 (75.2-84.9) * % Foster GR. N Engl J Med 2015; 373: 2608-17

4 ASTRAL-3 SVR 12 by cirrhosis or treatment history ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3 197808320620471 187 No cirrhosisCirrhosisTreatment-naïveTreatment-experienced SVR 12 in cirrhosis : SOF/VEL group : 93% if treatment-naïve ; 89% if treatment-experienced SOF + RBV group : 73% if treatment-naïve ; 58% if treatment-experienced 7 relapses 22 relapses 6 other 4 relapses 2 other 15 relapses 13 other 7 relapses 1 non-response 23 relapses 2 other SOF/VELSOF + RBV 100 80 60 40 20 0 87 (82-92) 97 94-99) 66 (55-76) 91 (83-96) 86 (81-91) 97 (94-99) 63 (51-75) 90 (81-96) 4 relapses 2 other 16 relapses 8 other Foster GR. N Engl J Med 2015; 373: 2608-17

5 ASTRAL-3 Characteristics of patients receiving SOF/VEL who relapsed ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3 Age, sex, raceGTCirrhosisIL28B HCV RNA (log 10 IU/ml) Timing of virologic failure HCV treatment history Resistance-associated variants NS5A NS5B Baseline and follow-up W12 BaselineFU W12BL 56, F, White3aYesCC6.9FU W4NaïveY93H (15.2%)Y93H (> 99%)None 58,M, White3aYesCC6.3FU W12ExperiencedNoneY93H (> 99%)None 61, M, White3aYesCT6.0FU W12NaïveY93H (> 99%) None 61 / M /White3aNoTT5.5FU W4ExperiencedNoneY93H (> 99%)None 50, M, White3aNoCT6.5FU W4NaïveY93H (> 99%) None 56, M, White3aYesTT6.1FU W4ExperiencedNoneY93H (> 99%)None 45, M, White3NoCC6.9FU W4ExperiencedY93H (2.8%)Y93H (> 99%)None 46, M, White3aYesCT6.1FU W4ExperiencedA30K (> 99%) A30K (> 99%) Y93H (> 99%) None 57, M, White3aYesCT6.3FU W4NaïveNoneY93H (> 99%)None 56, M, White3aYesCT6.3FU W4ExperiencedNoneY93H (> 99%)None 39, M, White3aNoCC6.6FU W12ExperiencedNoneGT1a reinfection Foster GR. N Engl J Med 2015; 373: 2608-17

6 SOF/VEL 12 weeks N = 277 SOF + RBV 24 weeks N = 275 At least one adverse event88%95% Serious adverse events6 (2%)15 (5%) Grade 3-4 adverse events12 (4%)23 (8%) Discontinuation due to adverse event09 (3%) Death03 (< 1%) Adverse events in > 10% of patients Headache32% Fatigue26%38% Insomnia11%27% Nausea17%21% Nasopharyngitis12% Irritability8%15% Cough5%13% Pruritus3%13% Dyspepsia3%11% Grade 3-4 laboratory abnormalities7%17% Hemoglobin < 10 g/dl04% Lymphocyte count < 500/mm 3 34 Platelet count 25,000-50,000/mm 3 11 Total bilirubin > 2.5 mg/dl03 Adverse events, N (%) ASTRAL-3 ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3 Foster GR. N Engl J Med 2015; 373: 2608-17

7 ASTRAL-3 ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3  Summary –Rates of SVR 12 in every subgroup of patients with HCV genotype 3 were substantially higher among those who had received 12 weeks of SOF/VEL compared to 24 weeks of SOF + RBV, including patients with cirrhosis and previous treatment failure Overall SVR 12 of 95% with SOF/VEL for 12 weeks versus 80% with SOF + RBV for 24 weeks (p < 0.001) 91% SVR 12 rate in patients with cirrhosis Limitation : small number of black patients –However, the rate of SVR 12 was 88% among patients who had NS5A RAVs at baseline and 97% among those who did not, with the lowest rate (84%) observed among patients with the Y93H variant at baseline –SOF/VEL was well tolerated and, compared with SOF + RBV, lacked toxicities commonly associated with RBV –For patients with HCV genotype 3 infection, SOF/VEL for 12 weeks represents an improvement over standard treatment with 24 weeks of SOF + RBV, with a simple and highly effective regimen, together with shorter duration of treatment and fewer side effects, owing to the removal of RBV from the regimen Foster GR. N Engl J Med 2015; 373: 2608-17

Download ppt "SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir."

Similar presentations

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
No prior therapy with PI

No prior therapy with PI
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:

Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
OBV/PTV/r Open label 18-70 years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.

COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
AI444040 Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI444040 Study: DCV + SOF + RBV for genotypes 1, 2 and.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
No HBV or HIV co-infection

No HBV or HIV co-infection
SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.

SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.
SMV 150 + SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : 1 18-70 years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥ 10.000.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind 18-70 years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

Similar presentations

Ads by Google